Phase I/II Study of Vorinostat and Gefitinib in Relapsed/ or Refractory Patients With Advanced Non-small Cell Carcinoma (NSCLC).

Trial Profile

Phase I/II Study of Vorinostat and Gefitinib in Relapsed/ or Refractory Patients With Advanced Non-small Cell Carcinoma (NSCLC).

Completed
Phase of Trial: Phase I/II

Latest Information Update: 01 Mar 2015

At a glance

  • Drugs Gefitinib (Primary) ; Vorinostat (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Apr 2014 Primary endpoint 'Progression-free-survival-duration' has not been met.
    • 09 Apr 2014 Results presented at the 105th Annual Meeting of the American Association for Cancer Research.
    • 13 Nov 2013 Planned end date changed from 1 Dec 2012 to 1 Mar 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top